Abstract Most neuronal nicotinic acetylcholine receptors are heteropentamers, composed of α and subunits. Mice lacking the α3 subunit and mice lacking both the 2 and 4 subunits, but not mice lacking the 2 or 4 subunits alone, have a severe phenotype characterized by megacystis, failure of bladder strips to contract in response to nicotine, widely dilated ocular pupils, growth failure, and perinatal mortality. The deficit in bladder contraction was also found in mice lacking only the 4 subunit, although they did not develop megacystis. The major bladder phenotype resembles the human autosomal recessive disorder of megacystis-microcolon-hypoperistalsis syndrome (MMIHS). Based on the similarity of the mouse and human phenotypes, we initiated mutation analyses in the α3 and 4 genes in MMIHS families. The human gene encoding the 4 subunit was fully characterized, including refinement of its mapping. Analysis of disease families and controls identified numerous genetic variants, including high-frequency polymorphisms in both CHRNA3 and CHRNB4. Although no loss-of-function mutations have been identified to date, these genes remain strong candidates for involvement in MMIHS, because various mutations might be obscured within the complex cluster of genes. Some of the markers presented here are valuable tools for analysis of the role of genetic variation in responses to nicotine and for characterization of various dysautonomic abnormalities.
Introduction
The neuronal nicotinic acetylcholine receptor (nAChR) subunits are widely expressed throughout the central nervous system (CNS) and the peripheral nervous system, including its autonomic components. The neuronal nAChR are pentamers made up of α and subunits (Anand et al. 1991; Karlin 1993) . There are at least eight α subunits (α2-α9) and three subunits ( 2-4) encoded by 11 distinct genes. The subunit composition of the native, usually heteropentameric, receptors as they relate to specific functions is generally unknown.
To resolve the composition and functions of the different subunits, our laboratory had previously prepared null mice for several neuronal nicotinic acetylcholine receptors. Mice lacking the α3 subunit, although born alive in the expected Mendelian ratios, have impaired growth and increased perinatal mortality (Xu et al. 1999a) . Multiorgan dysfunction, reflecting effects on the autonomic nervous system, is the major phenotypic finding. The null mice demonstrate bladder distension, urinary retention with secondary infection and bladder stones, dilated ocular pupils, and, possibly, hypoperistalsis (Xu et al. 1999a) . Similar phenotypic traits are found in mice homozygous for null mutations in both the 2 and 4 subunits (Xu et al. 1999b) . These findings in the α3 and the 2/ 4 null mice resemble the human autosomal recessive disorder known as megacystis-microcolonhypoperistalsis syndrome (MMIHS, OMIM 249210) and perhaps the related phenotype of intestinal pseudoobstruction (OMIM 243180), isolated or in association with megacystis. Further analysis of bladder function in the α3 and 2/ 4 null mice suggested that neuronal nAChRs containing α3 and 4 subunits are most prominently involved in bladder contractility, with the 2 subunits able to participate, but less significantly (De Biasi et al. 2000; Xu et al. 1999a; Xu et al. 1999b) . This is based on the finding that bladder strips from 2 null mice contract in response to nicotine, while those from α3 or 4 null mice do not, although neither the 2 or 4 single homozygotes develop megacystis, while the 2/ 4 double null and α3 single null mice have megacystis. These findings led to the hypothesis that altered α3 or 4 subunits underlie the MMIHS condition in humans. We therefore initiated mutational analyses in patients with this rare autosomal recessive condition.
Materials and methods

Patients and research subjects
We have studied 13 families, including seven individuals affected with MMIHS and their family members, three pairs of parents of deceased MMIHS-affected children, two individuals and their family members with the possibly related condition of intestinal pseudo-obstruction without megacystis, and one pair of parents of a deceased child with intestinal pseudo-obstruction. Most of the patients were referred from distant cities through other physicians, or they contacted the investigators through the American Society of Pseudo-obstruction and Hirschsprung's Disease (APHS). All blood samples were collected after the signing of an informed consent form as part of an approved Closing gaps within the CHRNB4 and CHRNA3 genes Since this study was completed, the sequence of the CHRNB4/A3/A5 gene cluster has appeared in the database (AC067863) as ten unordered contigs, with gaps in introns 1 and 4 in the CHRNB4 and CHRNA3 genes, respectively. Based on our cloning efforts, the size of CHRNB4 IVS1 was predicted to be between 3.7kb and 7.5 kb. To close the gap in IVS1 of CHRNB4, we designed the following primers, based on the available intronic sequences from contigs V and VII: forward, 5Ј-CGCCTTCCCTGGTCCTT-3Ј and reverse 5Ј-AGGGAGACTCAGAGGAGACT-3Ј, and amplified bacterial artificial chromosome (BAC)s 252H1 or 136A3 at an annealing temperature of 62°C. Previous work on the CHRNA3 gene (Rempel et al. 1998) did not define the size of IVS4. To close the gap in IVS4 of CHRNA3, we designed the following primers according to contigs VII and IX: forward 5Ј-GGCTGGACTGTGGGACA-3Ј and reverse 5Ј-ACCAGGTTCAAGCGATTCT and amplified BACs 192B14 or 136A3 at an annealing temperature of 62°C.
Screening for mutations
Genomic DNA was amplified using primers flanking the intron-exon boundaries of both the CHRNA3 gene (polymerase chain reaction [PCR] conditions and primers are available as electronic supplementary material) and the CHRNB4 gene (Table 1) . For the CHRNB4 gene, PCR reactions were performed using a standard protocol in the presence of 5% dimethylsulfoxide (DMSO). PCR fragments were either analyzed by denaturing highperformance liquid chromatography (DHPLC) or by direct sequencing, using the ABI PRISM big dye primer or big dye terminator ready reaction kits on the ABI 377 DNA sequencer (Applied Biosystems, Foster City, CA, USA).
Establishing conditions for DHPLC DHPLC analysis (Underhill et al. 1996) was run on a WAVE apparatus from Transgenomics (Omaha, NE, USA). DNA was eluted within a linear acetonitrile gradient consisting of buffer A (0.1 M triethylammonium acetate [TEAA]) / buffer B (0.1 M TEAA, 25% acetonitrile). DHPLC gradients for analysis of the CHRNB4 gene were all run over 5 min as follows: exon 1, buffer B from 56%-70% at 67°C; exons 2 and 4, buffer B from 54%-68% at 64°C; exon 3, buffer B from 51%-65% at 61°C; exon 5 upstream and downstream, buffer B from 54%-68% at 63°C; exon 5 middle, buffer B from 56%-70% at 63°C; exon 6, buffer B from 48%-62% at 64°C.
Mapping of the CHRNB4 gene
The GeneBridge 4 radiation hybrid panel (Research Genetics, Huntsville, AL, USA) (Walter et al. 1994 ) was used for PCR-based mapping of CHRNB4 exon 3 (primers listed in Table 1 ). Results were scored using the WICGR program (http://carbon.wi.mit.edu:8000/cgi-bin/contig/rhmapper.pl).
Results
Mutation analysis in the α3 nAChR gene (CHRNA3)
Based on the previous findings of an MMIHS-like phenotype in mice lacking the α3 neuronal nAChR (Xu et al. 1999a ), we conducted a search for mutations in patients with MMIHS. Genomic DNA was screened for mutations by PCR, followed by direct sequencing of all coding exons of the CHRNA3 gene. Although disease-causing mutations were not identified, a previously reported (Rempel et al. 1998 ) single amino-acid insertion in the signal peptide region (L17insL) and multiple previously unreported single-nucleotide polymorphisms (SNPs) were identified. We found three silent changes in the coding sequence:
345A AE G, 477G AE A, and 831C AE T, that are base pair substitutions in Val52, Lys96, and Tyr214, respectively. In addition, we found six changes within the introns and the 3Јuntranslated region (UTR) sequences: IVS1 ϩ 11A AE G, IVS1 ϩ 112C AE T, IVS2-34insG, IVS3-64A AE C, IVS3-5T AE C, and 1857insA (Table 2 , left panels). All of the silent and intronic changes were found both in patient families and in controls. Interestingly, the IVS3-64A AE C, IVS3-5T AE C, and 477G AE A were found in strict linkage disequilibrium and in high frequency in normal chromosomes (46%; Table 2 , left panels).
Characterization of the human 4 subunit of the nicotinic acetylcholine receptor gene (CHRNB4)
Because no loss-of-function mutations were identified in the CHRNA3 gene, we began a mutation screen in the second candidate gene, CHRNB4. We determined the exon-intron boundaries of CHRNB4 by PCR-based BAC screening and subcloning of restriction digest fragments hybridizing to exon-specific oligonucleotides (data not shown GenBank AF306325, AF306326, AF306327, AF306328, AF306329). A summary of the genomic structure with intron/exon junctions is presented in Table 3 , including the sizes of introns and exons. By the time of completion of this study, the sequence of the BAC containing the CHRNB4/A3/A5 gene cluster had appeared in the database (AC067863) however, there were gaps within the relevant genes. To close the gap in IVS1 of CHRNB4, we PCR-amplified and cloned a 3.5-kb fragment and further sequenced it from both cloning ends. Sequencing of this band closed the gaps between three different contigs in AC067863 and revealed the complete IVS 1, which spans over 5492 bp (GenBank AY027915, AY027916). To close the gap in CHRNA3 IVS4, we PCR-amplified the 192B14 and 252HI BACs with primers designed according to contigs VII and IX, and subcloned the products. We found two groups of subclones: one with a total length of 452 bp that was sequenced successfully and deposited in GenBank (AY027912), and the other with a total length of approximately 650 bp that could not be completely sequenced from either end (GenBank AY027913, AY027914). Comparison of the sequence of both types of clones suggested that the shorter clones may arise due to an inverted repeat sequence in the region. Therefore, we predict that the correct size of this gap is 650 bp, which indicates that the size of intron 4 of CHRNA3 is 14.59 kb.
Refinement of the CHRNB4 mapping
The CHRNB4 locus was originally mapped to chromosome 15q24 (Raimondi et al. 1992 ) in a cluster with CHRNA3 and CHRNA5. Recently, Bonati et al. (2000) genetically mapped this cluster between D15S1027 and D15S1005 upstream of the region involved in autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE). Using the genomic sequence of CHRNB4, we now refined its mapping by direct amplification from intronic sequences adjacent to exon 3 and scoring on a radiation hybrid panel. By this analysis we localized the CHRNB4 gene 3.1 cR downstream from WI-7183, which lies on the distal end of 15q24.3, and 14.3 cR upstream of WI-6335, which lies in 15q25.1-15q25.3.
Polymorphisms in the CHRNB4 gene
All coding exons of the CHRNB4 gene were amplified with the primers shown in Table 1 located in the adjacent introns. As with the CHRNA3 gene, multiple variations were found in both coding and noncoding sequences of CHRNB4. Most of the variations found in the patient families were either intronic changes (IVS1ϩ53G AE T, IVS1-91T AE G and IVS2-47G AE C) or changes within the 3ЈUTR sequence. The IVS1ϩ53G AE T, although not found in controls, appeared only in an unaffected sibling and her mother, and therefore is not implicated in MMIHS. The 3ЈUTR changes included the 1693C AE T, which was present on 50% of 30 Caucasians; chromosomes, and the more rare change 1775G AE A, which was seen in several unrelated MMIHS families and in one family only in an unaffected sibling (Table 2 , right panels). All the other changes listed in Table 2 were observed in controls and are therefore interpreted as not causing MMIHS. Two amino acid substitutions, T81I and M467V, were found originally in two MMIHS families, but subsequently in controls, suggesting that these are benign polymorphisms. We identified additional variants, using DHPLC to screen control samples for the previously identified variants. In effect, we screened between 190 and 295 normal unrelated individuals for alterations in exons 4, 5, or 6, using DHPLC. The additional changes found initially in the normal samples include S140G, 840C AE T, and the more rare variants R136W and 573C AE T.
Possible alternative exon in CHRNB4
Although the CHRNB4 gene is expressed primarily in the nervous system, we attempted to detect its mRNA in lymphoblastoid cells from MMIHS families. By this method, using nested reverse transcription (RT)-PCR, we identified an alternatively spliced mRNA from the healthy sibling of a patient. This spliced mRNA included a cryptic exon of 34 bases (designated 4a GenBank AF306327, not shown) between exon 4 and exon 5. The genomic sequence of exon 4a lies in intron 4 and includes the conserved AG/GT splice sites. This mRNA, if translated, is predicted to produce a shorter protein that reads through exon 4a to exon 5, with a stop codon at nucleotide 494, which is between amino acids Y115 and E116. However, because no genomic alterations were found in the sequence adjacent to exon 4a in this family, this transcript may represent either a splicing error or, potentially, a biologically functional isoform.
Discussion
In this report, we describe the characterization of the human gene for the 4 subunit of nAChR and the refinement of its chromosomal localization. We also report the finding of multiple polymorphic variants within the CHRNA3 and CHRNB4 genes that may be useful for studies of responses to nicotine and of disorders that involve the nervous system, perhaps, especially, the autonomic components. The functional 4 nAChR subunit cDNA is formed by splicing of the six coding exons of the CHRNB4 gene. The additional exon found in this study (designated as exon 4a) is spliced between exon 4 and 5 and could represent a splicing error, or an exon of unknown biological significance. The complex genomic structure of the CHRNB4/A3/ A5 gene cluster (Raimondi et al. 1992 ) may predispose to rearrangement events between the CHRNB4 and/or the related CHRNA3 and/or CHRNA5 genes. In this study we have found multiple polymorphic markers in CHRNA3 and CHRNB4. These changes included the insertion of an amino acid, amino acid substitutions, intronic changes, and many silent changes within the coding sequence. The more frequent variations in CHRNA3 included the three polymorphisms in tight linkage disequilibrium in exon 4 (IVS3-64A AE C, IVS3-5T AE C, and 477G AE A), the 831C AE T, and the insertion of an adenosine (1857insA) in a stretch of ten adenosine nucleotides. The most frequent variation in CHRNB4 is a substitution of thymidine for cytosine (1693C AE T). These polymorphic changes would be informative tools for future association or linkage studies for either the effects of nicotine on smokers or for other diseases involving the autonomic nervous system.
Although we did not find any loss-of-function mutations in either CHRNA3 or CHRNB4 genes in DNA from patients with MMIHS, further studies are warranted, given the strong similarity of the phenotypes in MMIHS and mutant mice.
